Literature DB >> 7520935

Pharmacologic treatment of thalassemia intermedia with hydroxyurea.

F M Hajjar1, H A Pearson.   

Abstract

Three adult patients with beta-thalassemia intermedia were treated with hydroxyurea. Each had a significant but transient rise in total hemoglobin level associated with a variable increase in hemoglobin F.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7520935     DOI： 10.1016/s0022-3476(05)83304-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  14 in total

1.  Dynamic posttranscriptional regulation of epsilon-globin gene expression in vivo.

Authors:  Zhenning He; J Eric Russell
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

2.  Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.

Authors:  Nicoletta Masera; Luisa Tavecchia; Marietta Capra; Giovanni Cazzaniga; Chiara Vimercati; Lorena Pozzi; Andrea Biondi; Giuseppe Masera
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

3.  Fetal globin induction--can it cure beta thalassemia?

Authors:  Susan P Perrine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

4.  Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives.

Authors:  Serguei Castaneda; Michael S Boosalis; David Emery; Allison Thies; Douglas V Faller; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2005 Sep-Oct       Impact factor: 3.039

5.  Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Authors:  Mehran Karimi; Sezaneh Haghpanah; Ali Farhadi; Majid Yavarian
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

6.  Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.

Authors:  Susan P Perrine; Serguei A Castaneda; Michael S Boosalis; Gary L White; Brandon M Jones; Regine Bohacek
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

7.  Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells.

Authors:  Elizabeth R Macari; Emily K Schaeffer; Rachel J West; Christopher H Lowrey
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

8.  A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.

Authors:  Suthat Fucharoen; Adlette Inati; Noppadol Siritanaratku; Swee L Thein; William C Wargin; Suzanne Koussa; Ali Taher; Nattawara Chaneim; Michael Boosalis; Ronald Berenson; Susan P Perrine
Journal:  Br J Haematol       Date:  2013-03-27       Impact factor: 6.998

9.  Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.

Authors:  Hassana Fathallah; Ali Taher; Ali Bazarbachi; George F Atweh
Journal:  Blood Cells Mol Dis       Date:  2009-04-05       Impact factor: 3.039

10.  Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

Authors:  Antara Banerjee; Sudipa Basu Chakrabarty; Susanta Roy Karmakar; Amit Chakrabarty; Surjyo Jyoti Biswas; Saiful Haque; Debarsi Das; Saili Paul; Biswapati Mandal; Boujedaini Naoual; Philippe Belon; Anisur Rahman Khuda-Bukhsh
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-29       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.